174 related articles for article (PubMed ID: 36167834)
21. Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing.
Zhu CY; Donangelo I; Gupta D; Nguyen DT; Ochoa JE; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1240-e1247. PubMed ID: 33394039
[TBL] [Abstract][Full Text] [Related]
22. Utility of mutational analysis for risk stratification of indeterminate thyroid nodules in a real-world setting.
Torrecillas V; Sharma A; Neuberger K; Abraham D
Clin Endocrinol (Oxf); 2022 Apr; 96(4):637-645. PubMed ID: 34605038
[TBL] [Abstract][Full Text] [Related]
23. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules.
Taye A; Gurciullo D; Miles BA; Gupta A; Owen RP; Inabnet WB; Beyda JN; Marti JL
Surgery; 2018 Jan; 163(1):97-103. PubMed ID: 29154079
[TBL] [Abstract][Full Text] [Related]
24. The utility of ThyroSeq
Li W; Justice-Clark T; Cohen MB
Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382
[TBL] [Abstract][Full Text] [Related]
25. Molecular Testing Results for Indeterminate Thyroid Nodules and Social Habits.
Zheng H; Whitney JF; Lai V
J Surg Res; 2023 Apr; 284():245-250. PubMed ID: 36603517
[TBL] [Abstract][Full Text] [Related]
26. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
[TBL] [Abstract][Full Text] [Related]
27. The first Canadian experience with the Afirma® gene expression classifier test.
Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
[TBL] [Abstract][Full Text] [Related]
28. Quality of Life Following Molecular Marker Testing for Indeterminate Thyroid Nodules.
Wong CW; Schumm MA; Zhu CY; Tseng CH; Arasu A; Han J; Livhits MJ
Endocr Pract; 2020 Sep; 26(9):960-966. PubMed ID: 33471700
[TBL] [Abstract][Full Text] [Related]
29. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
Selvaggi SM
Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
[TBL] [Abstract][Full Text] [Related]
30. Using molecular testing to improve the management of thyroid nodules with indeterminate cytology: an institutional experience with review of molecular alterations.
Glass RE; Marotti JD; Kerr DA; Levy JJ; Vaickus LJ; Gutmann EJ; Tafe LJ; Motanagh SA; Sorensen MJ; Davies L; Liu X
J Am Soc Cytopathol; 2022; 11(2):79-86. PubMed ID: 34627720
[TBL] [Abstract][Full Text] [Related]
31. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
[TBL] [Abstract][Full Text] [Related]
32. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
33. Impact of a genomic classifier on indeterminate thyroid nodules: an institutional experience.
Abdelhakam DA; Mojica RE; Huenerberg KA; Nassar A
J Am Soc Cytopathol; 2021; 10(2):155-163. PubMed ID: 33067175
[TBL] [Abstract][Full Text] [Related]
34. Benign call rate and molecular test result distribution of ThyroSeq v3.
Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
[TBL] [Abstract][Full Text] [Related]
35. An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer.
Nicholson KJ; Yip L
Curr Opin Oncol; 2018 Jan; 30(1):8-15. PubMed ID: 29028645
[TBL] [Abstract][Full Text] [Related]
36. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
37. Utilities of
Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
[No Abstract] [Full Text] [Related]
38. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
39. The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.
Chen T; Gilfix BM; Rivera J; Sadeghi N; Richardson K; Hier MP; Forest VI; Fishman D; Caglar D; Pusztaszeri M; Mitmaker EJ; Payne RJ
Thyroid; 2020 Sep; 30(9):1280-1287. PubMed ID: 32242511
[No Abstract] [Full Text] [Related]
40. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
